Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

The effect of etanercept on Graves' ophthalmopathy: a pilot study

The effect of etanercept on Graves' ophthalmopathy: a pilot study CLINICAL STUDY Eye (2005) 19, 1286–1289 & 2005 Nature Publishing Group All rights reserved 0950-222X/05 $30.00 www.nature.com/eye 1 1 D Paridaens , WA van den Bosch , TL van der The effect 2 3 4 Loos , EP Krenning and PM van Hagen of etanercept on Graves’ ophthalmopathy: a pilot study Abstract Keywords: TNF; etanercept; ophthalmopathy; thyroid Purpose To assess the effect of etanercept, an antitumour necrosis factor (anti-TNF) drug, on clinical signs in Graves’ ophthalmopathy (GO). Introduction Methods A total of 10 consecutive patients (seven female, three male) with recent-onset, Although the pathogenesis of Graves’ active, mildly-to-moderately severe GO were ophthalmopathy (GO) remains incompletely treated with subcutaneous injections of 25 mg understood, cytokines appear to play a major etanercept (Enbrel ) twice weekly during 12 role in the initiation and maintenance of this weeks. The average age was 50 years (range: disorder. One of these cytokines, tumour 39–59 years). The average duration of GO was necrosis factor-a (TNF-a), has been shown to be Department of Oculoplastic 2,3 and Orbital Surgery, 4 months (range: 2–6 months). All patients of importance in GO and in other Rotterdam Eye Hospital, were at least 2 months euthyroid with autoimmune diseases, including rheumatoid http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Eye Springer Journals

The effect of etanercept on Graves' ophthalmopathy: a pilot study

Download PDF
4 pages

Loading next page...
 
/lp/springer-journals/the-effect-of-etanercept-on-graves-ophthalmopathy-a-pilot-study-Hm4459StTL

References (12)

Publisher
Springer Journals
Copyright
Copyright © 2005 by Royal College of Ophthalmologists
Subject
Medicine & Public Health; Medicine/Public Health, general; Ophthalmology; Laboratory Medicine; Surgery; Surgical Oncology; Pharmaceutical Sciences/Technology
ISSN
0950-222X
eISSN
1476-5454
DOI
10.1038/sj.eye.6701768
Publisher site
See Article on Publisher Site

Abstract

CLINICAL STUDY Eye (2005) 19, 1286–1289 & 2005 Nature Publishing Group All rights reserved 0950-222X/05 $30.00 www.nature.com/eye 1 1 D Paridaens , WA van den Bosch , TL van der The effect 2 3 4 Loos , EP Krenning and PM van Hagen of etanercept on Graves’ ophthalmopathy: a pilot study Abstract Keywords: TNF; etanercept; ophthalmopathy; thyroid Purpose To assess the effect of etanercept, an antitumour necrosis factor (anti-TNF) drug, on clinical signs in Graves’ ophthalmopathy (GO). Introduction Methods A total of 10 consecutive patients (seven female, three male) with recent-onset, Although the pathogenesis of Graves’ active, mildly-to-moderately severe GO were ophthalmopathy (GO) remains incompletely treated with subcutaneous injections of 25 mg understood, cytokines appear to play a major etanercept (Enbrel ) twice weekly during 12 role in the initiation and maintenance of this weeks. The average age was 50 years (range: disorder. One of these cytokines, tumour 39–59 years). The average duration of GO was necrosis factor-a (TNF-a), has been shown to be Department of Oculoplastic 2,3 and Orbital Surgery, 4 months (range: 2–6 months). All patients of importance in GO and in other Rotterdam Eye Hospital, were at least 2 months euthyroid with autoimmune diseases, including rheumatoid

Journal

Eye – Springer Journals

Published: Nov 19, 2004

There are no references for this article.